A Single Center, Randomized, Double Blind, Placebo Controlled, Multiple Dose Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects.
Latest Information Update: 24 Apr 2024
At a glance
- Drugs Pegylated exenatide/PB 722 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors PegBio
Most Recent Events
- 17 Apr 2024 Status changed from recruiting to completed.
- 29 Nov 2023 New trial record